Golidocitinib-based therapy for peripheral T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how well a medicine called golidocitinib, given alone or with other treatments, works for people with peripheral T-cell lymphoma (a type of blood cancer). It is a real-world study, meaning it follows patients who are already receiving this treatment in regular medical care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with peripheral T-cell lymphoma.
- You started a treatment that includes golidocitinib within the last 3 months.
- You are willing to sign a form saying you understand and agree to be in the study.
- You can provide your medical records and history, including past treatments.
- You are able to follow the study's rules and attend appointments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill called golidocitinib for people newly diagnosed with certain types of peripheral T-cell lymphoma who have not been treated before. The goal is to see if it is safe and effective in shrinking or controlling the lymphoma.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This trial tests a combination of two drugs, golidocitinib and pomalidomide, for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or stopped responding to prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This study tests an oral pill called golidocitinib (a JAK1 inhibitor) as the first treatment for people newly diagnosed with peripheral T-cell lymphoma. The pill targets a pathway that cancer cells use to grow, and the goal is to shrink tumors or slow the disease.
This trial tests if taking golidocitinib pills after first treatment helps keep peripheral T-cell lymphoma from coming back. You'll either get the study drug or a placebo (no active drug), and your doctor will watch how you do.
Hear when a new Peripheral T-cell Lymphoma (PTCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.